MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares
In furtherance to the outcome letter dated July 08, 2022, we hereby enclose copies of newspaper advertisement dated July 11, 2022, published today in Business Standard (English All editions), Business Standard (Hindi All editions) and Navshakti (Marathi Mumbai edition). 
Pharma stock rallies 17% as board to consider bonus shares issue this week
Marksans Pharma's board will meet on July 8, 2022 to consider the proposal for bonus shares issue MARKSANS PHARMA LTD. - 524404 - Corporate Action-Intimation of Buy back
In terms of Regulation 29(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, 8th July, 2022 to consider the proposal for buyback of fully paid up equity shares of the Company upto such amount of the aggregate of Company's paid up equity share capital and free reserves as the Board may decide in accordance with the provisions of Section 68, 69 and 70 of the Companies Act, 2013 and the SEBI (Buyback of Securities) Regulations, 2018. MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Considering The Proposal For Buyback Of Equity Shares Of The Company
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/07/2022 ,inter alia, to consider and approve the proposal for buyback of fully paid up equity shares of the Company upto such amount of the aggregate of Company's paid up equity share capital and free reserves as the Board may decide in accordance with the provisions of Section 68, 69 and 70 of the Companies Act, 2013 and the SEBI (Buyback of Securities) Regulations, 2018. It is further submitted that in terms of the Company''s Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the shares of the Company for the designated person(s) is already closed w.e.f. July 01, 2022 and will remain closed till 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2022. MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
In terms of the Company''s Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the shares of Marksans Pharma Limited ('the Company') for the designated person(s) of the Company will remain closed from Friday, 1st July, 2022 till 48 hours after the declaration of unaudited financial results for the quarter ended 30th June, 2022. The date of declaration of financial results will be intimated separately in due course of time. Designated Persons of the Company and/or their immediate relatives shall not trade in the shares of the Company during the aforesaid period of closure of trading window. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Marksans Pharma Limited's wholly owned subsidiary Time-Cap Laboratories Inc. recalls Kroger Brand Aspirin (300 count bottles) and Ibuprofen (160 count bottles)due to label packaging issue to meet child resistant packaging requirement. Total 12 lots containing 209,430 units have been recalled MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Virtual Meeting with Analysts MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Further to our letter dated 25th April, 2022, kindly be informed that the Company has completed the process of acquiring 100% share capital of Access Healthcare for Medical Products LLC based in Dubai, UAE.